Business Context and Reporting Period
This Form 6-K filing by Scinai Immunotherapeutics Ltd. covers the month of March 2026, with the report dated March 19, 2026. The filing serves to disclose a material event regarding the company's stock listing status on the Nasdaq Stock Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an informational disclosure regarding a regulatory notification and does not contain financial statements or performance metrics.
Material Changes
On March 16, 2026, the company received a notification from Nasdaq indicating that its common stock was not in compliance with the minimum bid price requirement for continued listing. This represents a material change in the company's regulatory standing regarding its public listing.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future operations, or a detailed risk assessment beyond the immediate listing compliance issue. The primary contingency identified is the potential loss of Nasdaq listing status if the minimum bid price requirement is not met within the timeframe specified by the exchange.
Key Facts for Investor Verification
- Verify the specific Nasdaq compliance deadline and the required minimum bid price threshold.
- Review the full text of the press release (Exhibit 99.1) for any stated remediation plans or timelines.
- Monitor subsequent filings for updates on the company's compliance status or potential delisting proceedings.